Immutep Limited, incorporated in Australia on May 21, 1987, is a late-stage biotechnology company focused on the development of novel immunotherapies targeting the lymphocyte activating gene -3 (LAG-3) for the treatment of cancer and autoimmune diseases. As a pioneer in the science of LAG-3, Immutep has built a diverse portfolio of products designed to harness the body's immune system through innovative therapeutic mechanisms. The company's lead clinical candidate, eftilagimod alfa (IMP321), is a first-in-class fusion protein designed to enhance immune activation across various cancer types and is currently being investigated in several global clinical trials. In addition to the field of oncology, Immutep is developing LAG-3 agonists for autoimmune diseases and collaborating with major research institutions and pharmaceutical partners.